- Prescription opioid abuse leads to opioid overdoses. Abusers tend to shift toward using illicit drugs over time.
- US FDA is lowering the hurdles for generic drug makers to develop abuse-deterrent formulations.
- While other formulations like crushed-resistant can help with the opioid abuse epidemic, NKTR-181 is seemingly the answer for solving the problem at the molecular level.
- This is an abbreviated version of the in-depth Integrated BioSci Report available in advanced to our marketplace subscribers.
On Nov. 21, 2017, the US FDA Commissioner David Gottlieb, issued a release (which provided the guidance for the development of generic abuse-deterrent opioids). The efforts stemmed from the agency’s increasing focus on solving the epidemic of prescriptions opioids abuse. The aforesaid development has important ramifications for Nektar Therapeutics (NASDAQ:NKTR), a bioscience focusing on the innovation and development of therapeutics to service the immuno-oncology, autoimmune diseases, and chronic pain markets. Since our initial recommendation, Nektar has catapulted more than 2X in its share price to deliver over 202% profits for subscribers of Integrated BioSci Investingmarketplace. In this report, we’ll explore this news in further details in the context of how it affects Nektar.
Today, six out of ten drug overdose-deaths in the US are due to opioid abuse. Each day, there are over 1,000 people treated in the ED for using opioids not as directed (per figure 2). From 1999 to 2010, the numbers of prescription opioids sold to pharmacies, hospitals, and doctors’ offices increased by roughly four-fold. Moreover, deaths from prescription opioids increased over 400% (of which, the most common abusing drugs are oxycodone, hydrocodone, and methadone). Additionally, research shows that those who abused prescription opioids tend to switch to illicit drugs use like heroin over time.